Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

類似資料

• Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
  著者:: Xu, Fengrui, 等
  出版事項: (2019)
• A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients
  著者:: Wang, Tao, 等
  出版事項: (2019)
• Erratum to prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer
  著者:: Xu, Fengrui, 等
  出版事項: (2020)
• A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
  著者:: Tirelli, Umberto, 等
  出版事項: (2020)
• Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study
  著者:: Ma, Jun, 等
  出版事項: (2021)